Expert Perspectives delivers health care providers with insights from key thought leaders on the latest advancements and current practices in medic......READ MORE
by Harry Paul Erba, MD, PhD; Guillermo Garcia-Manero, MD; and David Sallman, MD
Future paradigms for high-risk myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) might involve combinations of targeted therapies and......READ MORE
by Harry Paul Erba, MD, PhD; Guillermo Garcia-Manero, MD; and David Sallman, MD
Actionable mutations now allow for a more individualized approach to the treatment of acute myeloid leukemia (AML) than in the past. Further, patie......READ MORE
Advancements in uncovering the underlying pathogenesis of myelodysplastic syndrome (MDS) have led to the development of investigational therapies f......READ MORE
The US Food and Drug Administration approval of lower-intensity treatments, including hypomethylating agents (HMAs) and targeted and/or immunomodul......READ MORE
Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) are part of a disease spectrum that is beginning to enter into the precision medici......READ MORE